最新ニュース CureVac (NASDAQ:CVAC) 株価情報

CureVac

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

CureVac NV

Lumentum Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NYSE">LITE</a>) short percent of float has fallen 7.16% since its last report. The company recently reported that it has 10.58 million shares sold short, which is 20.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.34 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Lumentum Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739279713_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Lumentum Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Lumentum Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Lumentum Holdings's peer group average for short interest as a percentage of float is 5.96%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

LITE

Peering Into Lumentum Holdings's Recent Short Interest

WIIM

Humana shares are trading higher after following a Q4 revenue beat.

U.S. stock futures were lower this morning, with the Nasdaq futures falling around 100 points on Tuesday.
Shares of Harmonic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) fell sharply in today's pre-market trading after the company issued <a href="https://www.benzinga.com/quote/HLIT/earnings">first-quarter earnings and revenue guidance below estimates.</a>
The company said it sees first-quarter adjusted earnings of 2 cents to 8 cents per share, versus estimates of 14 cents per share. The company expects revenue of $120 million to $135 million versus projections of $154.76 million.
Harmonic shares dipped 25.6% to $8.27 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Fluence Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) shares fell 35.1% to $8.48 in pre-market trading after the company reported worse-than-expected first-quarter financial results and issued FY25 revenue guidance below estimates.</li>
<li>Surgery Partners, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>) fell 10.1% to $23.00 in pre-market trading</li>
<li>Amkor Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) fell 9.5% to $22.04 in pre-market trading after the company missed fourth-quarter revenue estimates.</li>
<li>Axcelis Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLS#NASDAQ">ACLS</a>) shares dipped 8.3% to $62.00 in pre-market trading following fourth-quarter results.</li>
<li>Medpace Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) declined 6.6% to $331.17 in pre-market trading following fourth-quarter results.</li>
<li>Surgery Partners, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>) fell 6.1% to $24.02 in pre-market trading.</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) fell 6% to $15.66 in pre-market trading.</li>
<li>CoreCivic, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXW#NYSE">CXW</a>) fell 5.2% to $17.86 in pre-market trading after the company issued FY25 FFO guidance below estimates.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/25/02/43592071/top-3-tech-stocks-that-may-jump-this-month">Top 3 Tech Stocks That May Jump This Month</a></li>
</ul>

News

Pre-Market Outlook

Markets

Movers

ACLS

AMKR

FLNC

HLIT

MEDP

SGRY

XPEV

Harmonic Issues Weak Guidance, Joins Fluence Energy, Amkor Technology And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Carlyle Group shares are trading lower after the company reported Q4 financial results and missed its adjusted EPS and revenue estimates.

Piper Sandler analyst Jessica Tassan maintains Health Catalyst (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>) with a Overweight and lowers the price target from $12 to $8.

Price Target

Analyst Ratings

HCAT

Piper Sandler Maintains Overweight on Health Catalyst, Lowers Price Target to $8

Jerash Holdings (US) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRSH#NASDAQ">JRSH</a>) reported quarterly sales of $35.38 million which missed the analyst consensus estimate of $37.65 million by 6.02 percent. This is a 28.58 percent increase over sales of $27.52 million the same period last year.

Earnings

Earnings Misses

JRSH

Jerash Holdings (US) Q3 Sales $35.38M Miss $37.65M Estimate

SPGI

S&P Global shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY25 revenue guidance above estimates. The company also authorized a $4.3 billion share repurchase program.

D. Boral Capital analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) with a Buy and maintains $5 price target.

HOTH

D. Boral Capital Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target

Piper Sandler analyst Alexander Goldfarb maintains AvalonBay Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVB#NYSE">AVB</a>) with a Overweight and lowers the price target from $270 to $265.

Piper Sandler Maintains Overweight on AvalonBay Communities, Lowers Price Target to $265

TRNR

Interactive Strength To Acquire Sportstech Holding; To Acquire 99% Of Sportstech In All-Stock Transaction With Initial Consideration Of $15M In Non-Voting Convertible Preferred Stock

Canadian Prime Minister Justin Trudeau on Tuesday highlighted the adverse effects of the U.S. steel and aluminum tariffs and warned of a strong response if required.
What Happened: Trudeau criticized the recent tariffs calling them &#8220;Unacceptable&#8221; and said &#8220;Canadians will stand up strongly and firmly if we need to,&#8221; reported Reuters.
On Monday, U.S. President Donald Trump signed orders to increase tariffs on <a href="https://www.benzinga.com/markets/equities/25/02/43613133/trumps-25-tarrifs-a-self-inflicted-wound-says-economist-amid-warnings-of-fewer-american-jobs-peter-schiff-says-youll-pay-more-for-cars-and-homes">steel and aluminum imports to 25%</a> without exceptions. This decision, effective Mar 4, intended to boost the struggling industry, could escalate into a wider trade conflict.
SEE ALSO: <a href="https://www.benzinga.com/25/02/43616261/trumps-punitive-tariffs-could-lead-to-us-job-losses-warns-former-ambassadorwere-in-for-a-bit-of-bad-news-in-the-near-term">Trump&#8217;s &#8216;Punitive&#8217; Tariffs Could Lead To US Job Losses, Warns Former Envoy: &#8216;We&#8217;re In For A Bit Of Bad News In The Near Term&#8217;</a>
Why It Matters: This development comes amid escalating tensions between the two nations. Earlier this month, Trudeau expressed concerns over Trump&#8217;s threat to annex Canada. He suggested that Trump&#8217;s interest in making <a href="https://www.benzinga.com/25/02/43582659/trump-says-canada-much-better-off-being-the-51st-state-the-border-with-us-is-just-a-line">Canada the &#8220;51st state&#8221;</a> was driven by a desire to access the country&#8217;s critical minerals. According to&nbsp;the American Iron and Steel Institute, approximately 80% of U.S. primary aluminum imports were from Canada. 
President of the Canadian Labour Congress, Bea Bruske, recalled Trump's previous steel and aluminum tariffs and stated that it had a "devastating impact" on the workers in the country. "Thousands of workers faced layoffs and uncertainty, and the effects rippled across manufacturing, construction and supply chains," stated Bruske.
Minister of Innovation, Science and Industry of Canada, François-Philippe Champagne, called the U.S. tariffs &#8216;totally unjustified&#8217; and stated, &#8220;We are consulting with our international partners as we examine the details. Our response will be clear and calibrated.&#8221;
Trump&#8217;s tariffs on steel and aluminum are set to ripple across key U.S. industries, driving up costs for manufacturers and consumers alike. The automotive sector, including Ford (NYSE F), General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>), and Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), faces higher production expenses, while aerospace giants like Boeing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) and Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) may see increased material costs. The construction and infrastructure industry is also expected to feel the impact. According to <a href="https://www.barrons.com/articles/trump-steel-tariffs-car-prices-707e1af4">Barron&#8217;s</a>, the tariffs could add as much as $2,000 to the price of a new car.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/news/25/02/43543459/i-love-canada-more-than-i-love-spotify-canadians-are-canceling-netflix-amazon-disney-and-spotify-en-masse-despite-the-tariff-pause">&#8216;I Love Canada More Than I Love Spotify&#8217;—Canadians Are Canceling Netflix, Amazon, Disney+, And Spotify En Masse, Despite The Tariff Pause</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Economics

TSLA

Justin Trudeau Slams 'Unacceptable' US Tariffs After Trump Imposes 25% Levy On Metal Imports : 'Canadians Will Stand Up Strongly And Firmly If We Need To'

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

LMFA

LM Funding America Mined 8 Bitcoin In Jan.

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">91.03</td>
<td align="right">0.52</td>
<td align="right">0.57</td>
<td>27.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">80.01</td>
<td align="right">0.17</td>
<td align="right">0.21</td>
<td>749</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">235.50</td>
<td align="right">-0.72</td>
<td align="right">-0.31</td>
<td>19.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">103.00</td>
<td align="right">-0.20</td>
<td align="right">-0.20</td>
<td>618</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">78.89</td>
<td align="right">-0.10</td>
<td align="right">-0.13</td>
<td>1.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">138.51</td>
<td align="right">-0.05</td>
<td align="right">-0.04</td>
<td>844</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.40</td>
<td align="right">-0.01</td>
<td align="right">-0.02</td>
<td>42.8K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

ETFs

Leading And Lagging Sectors For February 11, 2025

Ecolab shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY25 adjusted EPS guidance above estimates.

Mizuho analyst Vijay Rakesh maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Outperform and lowers the price target from $85 to $71.

Mizuho Maintains Outperform on ON Semiconductor, Lowers Price Target to $71

INAB

IN8bio shares are trading higher after the company announced new clinical data from the ongoing Phase 1 investigator-sponsored trial of INB-100.

Phillips 66 shares are trading higher after activist investor Elliott Investment Management disclosed a $2.5 billion stake in the company.

JP Morgan analyst Mark Murphy maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Overweight and raises the price target from $635 to $725.

HUBS

JP Morgan Maintains Overweight on HubSpot, Raises Price Target to $725

Buybacks

SRTS

Sensus Healthcare Resumes $3M Share Repurchase Program

Contracts

ROLR

High Roller Enters Into A Strategic Partnership With Yggdrasil

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company's shares closed yes...

Leerink Partners Sticks to Their Hold Rating for CureVac (CVAC)

Analyst Roy Buchanan of JMP Securities reiterated a Buy rating on CureVac (CVAC – Research Report), retaining the price target of $16.00. Roy Bucha...

CureVac: Strong Financial Position and Promising Pipeline Justify Buy Rating

California Gov. Newsom declares State of Emergency over bird flu

Vaccine stocks gain amid uptick in flu, COVID-19, RSV

Bird flu claims first U.S. life in Louisiana

Shares of Moderna (MRNA), one of a few drugmakers currently developing a vaccine for the H5N1 bird flu, were up nearly 10% in early trading after t...

Bird flu vaccine maker Moderna shares jump after first US death, Barron's says

Moderna, Novavax and other vaccine names extend gains amid COVID/flu concerns

Arbutus could benefit from Big Pharma bird flu vaccines: Jefferies

CureVac: Latest GBM Data Bodes Well For Next Program Check Point

Bird flu reaches NYC as live poultry markets shut down

ABUS

ARCT

BNTX

CSLLY

CVAC

GLAXF

MRNA

NVAX

ROIV

Press Releases

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza  mRNA Vaccine Program

CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

Events

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

CureVac to Present at the 12th International mRNA Health Conference

Management

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

JMP Securities

Leerink Partners

B of A Securities

SVB Securities

Comments

CureVac

ニュース

最新ニュース CureVac (NASDAQ:CVAC) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル